Structure-based reverse vaccinology failed in the case of HIV because it disregarded accepted immunological theory

International Journal of Molecular Sciences

Volumn 17, Issue 9, 2016, Pages

  Van Regenmortel, Marc H V ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

Antibody polyspecificity; Continuous epitope; Degeneracy of the immune system; Discontinuous epitope; Mimotope; Paradigms in vaccinology; Plasticity of viral proteins; Rational vaccine design; Structure based reverse vaccinology; V3 loop of HIV 1 spikes

Indexed keywords

B LYMPHOCYTE RECEPTOR; EPITOPE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MENINGOCOCCUS VACCINE; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY;

ANTIBODY COMBINING SITE; B LYMPHOCYTE; COMPLEMENTARITY DETERMINING REGION; CROSS REACTION; DRUG DESIGN; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENOME BASED REVERSE VACCINOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOASSAY; IMMUNOGENICITY; IMMUNOREACTIVITY; MOLECULAR MIMICRY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; OPEN READING FRAME; PROTEIN ENGINEERING; REVERSE VACCINOLOGY; REVIEW; STEREOSPECIFICITY; STRUCTURE ANALYSIS; STRUCTURE BASED REVERSE VACCINOLOGY; VACCINATION; VIRUS GENOME; X RAY CRYSTALLOGRAPHY;

EID: 84988643155     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms17091591     Document Type: Review

References (228)

1. Rappuoli, R. Reverse vaccinology, a genome-based approach to vaccine development. Vaccine 2001, 19, 2688–2691.
2. Adu-Bobie, J.; Arico, B.; Giuliani, M.M.; Seruto, D. The first vaccine obtained through reverse vaccinology: The serogroup B meningococcus vaccine. In Vaccine Design: Innovative Approaches and Novel Strategies; Rappuoli, R., Bagnoli, F., Eds.; Caister Academic Press: Norfolk, UK, 2011; pp. 225–241.
3. Rappuoli, R.; Bagnoli, F. Vaccine Design: Innovative Approaches and Novel Strategies; Caister Academic Press: Norfolk, UK, 2011.
4. Burton, D.R. Antibodies, viruses and vaccines. Nat. Rev. Immunol. 2002, 2, 706–713.
5. Walker, L.M.; Burton, D.R. Rational antibody-based HIV-1 vaccine design: Current approaches and future directions. Curr. Opin. Immunol. 2010, 22, 358–366.
6. Van Regenmortel, M.H.V. Two meanings of reverse vaccinology and the empirical nature of vaccine science. Vaccine 2011, 29, 7875.
7. Wyatt, R.; Kwong, P.D.; Desjardins, E.; Sweet, R.W.; Robinson, J.; Hendrickson, W.A.; Sodroski, J.G. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 1998, 393, 705–711.
8. Zwick, M.B.; Parren, P.W.; Saphire, E.O.; Church, S.; Wang, M.; Scott, J.K.; Dawson, P.E.; Wilson, I.A.; Burton, D.R. Molecular features of the broadly neutralizing immunoglobulin G1 b12 required for recognition of human immunodeficiency virus type 1 gp120. J. Virol. 2003, 77, 5863–5876.
9. Binley, J.M.; Lybarger, E.A.; Crooks, E.T.; Seaman, M.S.; Gray, E.; Davis, K.L.; Decker, J.M.; Wycuff, D.; Harris, L.; Hawkins, N. et al. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J. Virol. 2008, 82, 11651–11668.
10. Scheid, J.F.; Mouquet, H.; Feldhahn, N.; Seaman, M.S.; Velinzon, K.; Pietzsch, J.; Ott, R.G.; Anthony, R.M.; Zebroski, H.; Hurley, A.; et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 2009, 458, 636–640.
11. Pejchal, R.; Wilson, I.A. Structure-based vaccine design in HIV: Blind men and the elephant? Curr. Pharm. Des. 2010, 16, 3744–3753.
12. Kong, L.; Sattentau, Q.J. Antigenicity and immunogenicity in HIV-1 antibody-based vaccine design. J. AIDS Clin. Res. 2012.
13. Scarselli, M.; Aricò, B.; Brunelli, B.; Savino, S.; di Marcello, F.; Palumbo, E.; Veggi, D.; Ciucchi, L.; Cartocci, E.; Bottomley, M.J. et al. Rational design of a meningococcal antigen inducing broad protective immunity. Sci. Transl. Med. 2011, 3, 91ra62.
14. Pajon, R.; Beernink, P.T.; Granoff, D.M. Design of meningococcal factor H binding protein mutant vaccines that do not bind human complement factor H. Infect. Immun. 2012, 80, 2667–2677.
15. Dormitzer, P.R.; Grandi, G.; Rappuoli, R. Structural vaccinology starts to deliver. Nat. Rev. Microbiol. 2012, 10, 807–812.
16. Sundberg, E.J.; Mariuzza, R.A. Molecular recognition in antibody-antigen complexes. Adv. Prot. Chem. 2002, 61, 119–160.
17. Wyatt, R.; Sodroski, J. The HIV-1 envelope glycoproteins: Fusogens, antigens, and immunogens. Science 1998, 280, 1885–1888.
18. Zwick, M.B. The membrane-proximal external region of HIV-1 gp41: A vaccine target worth exploring. AIDS 2005, 19, 1725–1737.
19. Hoxie, J.A. Toward an antibody-based HIV-1. Annu. Rev. Med. 2010, 61, 135–152.
20. Mascola, J.R.; Montefiori, D.C. The role of antibodies in HIV vaccines. Annu. Rev. Immunol. 2010, 28, 413–444.
21. Klasse, P.J. The molecular basis of HIV entry. Cell. Microbiol. 2012, 14, 1183–1192.
22. Van Regenmortel, M.H.V. Requirements for empirical immunogenicity trials, rather than structure-based design, for developing an effective HIV vaccine. Arch. Virol. 2012, 157, 1–20.
23. Burton, D.R.; Ahmed, R.; Barouch, D.H.; Butera, S.T.; Crotty, S.; Godzik, A.; Kaufmann, D.E.; McElrath, M.J.; Nussenzweig, M.C.; Pulendran, B.; et al. A blueprint for HIV vaccine discovery. Cell Host Microbe 2012, 12, 396–407.
24. Hilleman, M.R. Impediments, imponderables and alternatives in the attempt to develop an effective vaccine against AIDS. Vaccine 1992, 10, 1053–1058.
25. Hilleman, M.R. Vaccines in historic evolution and perspective: A narrative of vaccine discoveries. Vaccine 2000, 18, 1436–1447.
26. Kusters, I.; Almond, J.W. Vaccine strategies. In Desk Encyclopedia of General Virology; Mahy, B.W.J., Van Regenmortel, M.H.V., Eds.; Elsevier Academic Press: Oxford, UK, 2010; pp. 381–389.
27. Virgin, H.W.; Walker, B.D. Immunology and the elusive AIDS vaccine. Nature 2010, 464, 224–231.
28. Chen, W.; Streaker, E.D.; Russ, D.E.; Feng, Y.; Prabakaran, P.; Dimitrov, D. Characterization of germline antibody libraries from human umbilical cord blood and selection of monoclonal antibodies to viral envelope glycoproteins: Implications for mechanisms of immune evasion and design of vaccine immunogens. Biochem. Biophys. Res. Commun. 2012, 417, 1164–1169.
29. Van Regenmortel, M.H.V. Specificity, polyspecificity, and heterospecificity of antibody-antigen recognition. J. Mol. Recognit. 2014, 27, 627–639.
30. Xiao, X.; Chen, W.; Feng, Y.; Zhu, Z.; Prabakaran, P.; Wang, Y.; Zhang, M.Y.; Longo, N.S.; Dimitrov, D.S. Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: Implications for evasion of immune responses and design of vaccine immunogens. Biochem. Biophys. Res. Commun. 2009, 390, 404–409.
31. Dimitrov, D.S. Therapeutic antibodies, vaccines and antibodyomes. MAbs 2010, 2, 347–356.
32. Mascola, J.R.; Haynes, B.F. HIV-1 neutralizing antibodies: Understanding nature’s pathways. Immunol. Rev. 2013, 254, 225–244.
33. Klein, F.; Diskin, R.; Scheid, J.F.; Gaebler, S.C.; Mouquet, H.; Georgiev, I.S.; Pancera, M.; Zhou, T.; Incesu, R.-B.; Fu, B.Z. et al. Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. Cell 2013, 153, 126–138.
34. Prabakaran, P.; Chen, W.; Dimitrov, D.S. The antibody germline/maturation hypothesis, elicitation of broadly neutralizing antibodies against HIV-1 and cord blood IgM repertoires. Front. Immunol. 2014, 5, 398.
35. Doria-Rose, N.A.; Joyce, M.G. Strategies to guide the antibody maturation process. Curr. Opin. Virol. 2015, 11, 137–147.
36. Van Oss, C.J. Hydrophobic, hydrophilic and other interactions in epitope-paratope binding. Mol. Immunol. 1995, 32, 199–211.
37. Li, H.; Dunn, J.J.; Luft, B.J.; Lawson, C.L. Crystal structure of Lyme disease antigen outer surface protein A complexed with an Fab. Proc. Natl. Acad. Sci. USA 1997, 94, 3584–3589.
38. Rosen, R. Life Itself; Columbia University Press: New York, NY, USA, 1991.
39. Chen, S.W.; Van Regenmortel, M.H.V.; Pellequer, J.L. Structure-activity relationships in peptide-antibody complexes: Implications for epitope prediction and development of synthetic peptide vaccines. Curr. Med. Chem. 2009, 16, 953–964.
40. Woodger, J.H. Biological Principles; Humanities Press: New York, NY, USA, 1967.
41. Demchenko, A.P. Recognition between flexible protein molecules: Induced and assisted folding. J. Mol. Recognit. 2001, 14, 42–61
42. Cohen, I.R.; Hershberg, U.; Solomon, S. Antigen-receptor degeneracy and immunological paradigms. Mol. Immunol. 2004, 40, 993–996.
43. Jimenez, R.; Salazar, G.; Baldridge, K.K.; Romesberg, F.E. Flexibility and molecular recognition in the immune system. Proc. Natl. Acad. Sci. USA 2003, 100, 92–97.
44. Edmundson, A.B.; Ely, K.R.; Herron, J.N.; Cheson, B.D. The binding of opioid peptides to the MCG light chain dimer: Flexible keys and adjustable locks. Mol. Immunol. 1987, 24, 915–935.
45. Wilson, I.A.; Stanfield, R.L. Antibody-antigen interactions: New structures and new conformational changes. Curr. Opin. Struct. Biol. 1994, 4, 857–867.
46. Bosshard, H.R. Molecular recognition by induced fit: How fit is the concept? News Physiol. Sci. 2001, 16, 171–173.
47. Van Regenmortel, M.H.V. What is a B cell epitope? In Methods in Molecular Biology, Epitope Mapping Protocols; Reineke, U., Schutkowski, M., Eds.; Humana Press: New York, NY, USA, 2009; Volume 524, pp. 3–20.
48. Lescar, J.; Pellegrini, M.; Souchon, H.; Tello, D.; Poljak, R.J.; Peterson, N.; Greene, M.; Alzari, P.M. Crystal structure of a cross-reaction complex between Fab F9.13.7 and guinea fowl lysozyme. J. Biol. Chem. 1995, 270, 18067–18076.
49. Schroer, J.A.; Bender, T.; Feldmann, T.; Kim, K.J. Mapping epitopes on the insulin molecule using monoclonal antibodies. Eur. J. Immunol. 1983, 13, 693–700.
50. Edwards, B.M.; Barash, S.C.; Main, S.H.; Choi, G.H.; Minter, R.; Ullrich, S.; Williams, E.; DuFou, L.; Wilton, J.; Albert, V.R., et al. The remarkable flexibility of the human antibody repertoire; isolation of over one thousand different antibodies to a single protein, BLyS. J. Mol. Biol. 2003, 334, 103–118.
51. Liu, J.; Bartesaghi, A.; Borgnia, M.J.; Sapiro, G.; Subramaniam, S. Molecular architecture of native HIV-1 gp120 trimers. Nature 2008, 455, 109–113.
52. Van Regenmortel, M.H.V. Plant virus serology. Adv. Virus Res. 1966, 12, 207–271.
53. Van Regenmortel, M.H.V. The conformational specificity of viral epitopes. FEMS Microbiol. Lett. 1992, 100, 483–487.
54. Neurath, A.R.; Rubin, B.A. Viral structural components as immunogens of prophylactic value. In Monographs in Virology; Karger: Basel, Switzerland, 1971; p. 88.
55. Broder, C.C.; Earl, P.L.; Long, D.; Abedon, S.T.; Moss, B.; Doms, R.W. Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: Oligomer-specific and -sensitive monoclonal antibodies. Proc. Natl. Acad. Sci. USA 1994, 91, 11699–11703.
56. Gorny, M.K.; Stamatatos, L.; Volsky, B.; Revesz, K.; Williams, C.; Wang, X.H.; Cohen, S.; Staudinger, R.; Zolla-Pazner, S. Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles. J. Virol. 2005, 79, 5232–5237.
57. Bothner, B.; Dong, X.F.; Bibbs, L.; Johnson, J.E.; Siuzdak, G. Evidence of viral capsid dynamics using limited proteolysis and mass spectrometry. J. Biol. Chem. 1998, 9, 673–676.
58. Harris, A.; Borgnia, M.J.; Shi, D.; Bartesaghi, A.; He, H.; Pejchal, R.; Kang, Y.K.; Depetris, R.; Marozsan, A.J.; Sanders, R.W.; et al. Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures. Proc Natl. Acad. Sci. USA 2011, 108, 11440–11445.
59. Dey, B.; Svehla, K.; Xu, L.; Wycuff, D.; Zhou, T.; Voss, G.; Phogat, A.; Chakrabarti, B.K.; Li, Y.; Shaw, G. et al. Structure-based stabilization of HIV-1 gp120 enhances humoral immune responses to the induced co-receptor binding site. PLoS Pathog. 2009, 5, e1000445.
60. Moseri, A.; Tantry, S.; Sagi, Y.; Arshava, B.; Naider, F.; Anglister, J. An optimally constrained V3 peptide is a better immunogen than its linear homolog or HIV-1 gp120. Virology 2010, 401, 293–304.
61. Guenaga, J.; Dosenovic, P.; Ofek, G.; Baker, D.; Schief, W.R.; Kwong, P.D.; KarlssonHedestam, G.B.; Wyatt, R.T. Heterologous epitope-scaffold prime: Boosting immunofocuses B cell responses to the HIV-1 gp412F5 neutralization determinant. PLoS ONE 2011, 6, e16074.
62. Davies, D.R.; Padlan, E.A.; Sheriff, S. Antibody-antigen complexes. Annu. Rev. Biochem. 1990, 59, 439–473.
63. Goldbaum, F.A.; Schwarz, F.P.; Eisenstein, E.; Cauerhff, A.; Mariuzza, R.A.; Poljak, R.J. The effect of water activity on the association constant and the enthalpy of reaction between lysozyme and the specific antibodies D1.3 and D44.1. J. Mol. Recognit. 1996, 9, 6–12.
64. Schwartz, F.P.; Tello, D.; Goldbaum, F.A.; Mariuzza, R.A.; Poljak, R.J. Thermodynamics of antigen-antibody binding using specific anti-lysozyme antibodies. Eur. J. Biochem. 1995, 228, 388–394.
65. Ladbury, J.E. Just add water! The effect of water on the specificity of protein-ligand binding sites and its potential application to drug design. Chem. Biol. 1996, 3, 973–980.
66. Bhat, T.N.; Bentley, G.A.; Boulot, G.; Greene, M.I.; Tello, D.; Dall’Acqua, W.; Souchon, H.; Schwarz, F.P.; Mariuzza, R.A.; Poljak, R.J. Bound water molecules and conformational stabilization help mediate an antigen-antibody association. Proc. Natl. Acad. Sci. USA 1994, 91, 1089–1093.
67. Malby, R.L.; Tulip, W.R.; Harley, V.R.; McKimm-Breschkin, J.L.; Graeme Laver, W.; Webster, R.G.; Colman, P.M. The structure of a complex between the NC10 antibody and influenza virus neuraminidase and comparison with the overlapping binding site of the NC41 antibody. Structure 1994, 2, 733–746.
68. Chacko, S.; Silverton, E.; Kam-Morgan, L.; Smith-Gill, S.; Cohen, G.; Davis, D. Structure of an antibody–lysozyme complex unexpected effect of a conservative mutation. J. Mol. Biol. 1995, 245, 261–274.
69. Van Regenmortel, M.H.V. Immunoinformatics may lead to a reappraisal of the nature of B cell epitopes and of the feasibility of synthetic peptide vaccines. J. Mol. Recognit. 2006, 19, 183–187.
70. Van Regenmortel, M.H.V. Molecular dissection of protein antigens. In Structure of Antigens; Van Regenmortel, M.H.V., Ed.; CRC: Boca Raton, FL, USA, 1992; Volume 1, pp. 1–27.
71. Roberts, V.A.; Getzoff, E.D.; Tainer, J.A. Structure of Antigens; Van Regenmortel, M.H.V., Ed.; CRC: Boca Raton, FL, USA, 1993; Volume 3, pp. 31–53.
72. Laver, W.G.; Air, G.M.; Webster, R.G.; Smith-Gill, S.J. Epitopes on protein antigens: Misconceptions and realities. Cell 1990, 61, 553–556.
73. Lerner, R.A. Antibodies of predetermined specificity in biology and medicine. Adv. Immunol. 1984, 36, 1–44.
74. Darst, S.A.; Robertson, C.R.; Berzofsky, J.A. Adsorption of the protein antigen myoglobin affects the binding of conformation-specific monoclonal antibodies. Biophys. J. 1988, 53, 533–539.
75. Hans, D.; Young, P.R.; Fairlie, D.P. Current status of short synthetic peptides as vaccines. Med. Chem. 2006, 2, 627–646.
76. Spangler, B.D. Binding to native proteins by antipeptide monoclonal antibodies. J. Immunol. 1991, 146, 1591–1595.
77. Greenbaum, J.A.; Andersen, P.H.; Blythe, M.; Bui, H.-H.; Cachau, R.E.; Crowe, J.; Davies, M.; Kolaskar, A.S.; Lund, O.; Morrison, S. et al. Towards a consensus on datasets and evaluation metrics for developing B-cell epitope prediction tools. J. Mol. Recognit. 2007, 20, 75–82.
78. Zhang, Q.; Wang, P.; Kim, Y.; Haste-Andersen, P.; Beaver, J.; Bourne, P.E.; Bui, H.H.; Buus, S.; Frankild, S.; Greenbaum, J. et al. Immune epitope database analysis resource (IEDB-AR). Nucleic Acids Res. 2008, 36, W513–W518.
79. Van Regenmortel, M.H.V. Molecular dissection of protein antigens and the prediction of epitopes. In Synthetic Peptides as Antigens; Van Regenmortel, M.H.V., Muller, S., Eds.; Elsevier: Amsterdam, The Netherlands, 1999; pp. 1–78.
80. Van Regenmortel, M.H.V. Structural and functional approaches to the study of protein antigenicity. Immunol. Today 1989, 10, 266–272.
81. Trifilieff, E.; Dubs, M.C.; Van Regenmortel, M.H.V. Antigenic cross-reactivity potential of synthetic peptides immobilized on polyethylene rods. Mol. Immunol. 1991, 28, 889–896.
82. Benjamini, E. Immunochemistry of the tobacco mosaic virus. In Immunochemistry of Proteins; Atassi, M.Z., Ed.; Plenum Press: New York, NY, USA, 1997; Volume 2, pp. 265–310.
83. Chappey, O.; Debray, M.; Niel, E.; Schermann, J.M. Association constants of monoclonal antibodies for hapten: Heterogeneity of frequency distribution and possible relationship with hapten molecular weight. J. Immunol. Meth. 1994, 172, 219–225.
84. Morel-Montero, A.; Delaage, M. Immunochemistry of pharmacological substances. In Immunochemistry; Van Oss, C.J., Van Regenmortel, M.H.V., Eds.; Marcel Dekker: New York, NY, USA, 1994; pp. 357–372.
85. Geysen, H.M.; Rodda, S.J.; Mason, T.J. A priori delineation of a peptide which mimics a discontinuous antigenic determinant. Mol. Immunol. 1986, 23, 709–715.
86. Scala, G.; Chen, X.; Liu, W.; Telles, J.-N.; Cohen, O.J.; Vaccarezza, M.; Igarashi, T.; Fauci, A.S. Selection of HIV-specific immunogenic epitopes by screening random peptide libraries with HIV-1-positive sera. J. Immunol. 1999, 162, 6155–6161.
87. Zwick, M.B.; Bonnycastle, L.L.; Menendez, A.; Irving, M.B.; Barbas, C.F., 3rd; Parren, P.W.; Burton, D.R.; Scott, J.K. Identification and characterization of a peptide that specifically binds the human, broadly neutralizing anti-human immunodeficiency virus type 1 antibody B12. J. Virol. 2001, 75, 6692–6699.
88. Dorgham, K.; Dogan, I.; Bitton, N.; Parizot, C.; Cardona, V.; Debré, P.; Hartley, O.; Gorochov, G. Immunogenicity of HIV type 1 gp120 CD4 binding site phage mimotopes. AIDS Res. Hum. Retrovir. 2005, 21, 82–92.
89. Sundberg, E.J. Structural basis of antibody-antigen interactions. In Methods in Molecular Biology, Epitope Mapping Protocols; Reineke, U., Schutkowski, M., Eds.; Humana Press: New York, NY, USA, 2009; Volume 524, pp. 23–36.
90. Raghunathan, G.; Smart, J.; Williams, J.; Almagro, J.C. Antigen-binding site anatomy and somatic mutations in antibodies that recognize different types of antigens. J. Mol. Recognit. 2012, 25, 103–113.
91. Bhattacharjee, A.K.; Glaudemans, C.P. Dual binding specificities in MOPC 384 and 870 murine myeloma immunoglobulins. J. Immunol. 1978, 120, 411–413.
92. Laune, D.; Molina, F.; Ferrieres, G.; Mani, J.C.; Cohen, P.; Simon, D.; Bernardi, T.; Piechaczyk, M.; Pau, B.; Granier, C. Systematic exploration of the antigen binding activity of synthetic peptides isolated from the variable regions of immunoglobulins. J. Biol. Chem. 1997, 272, 30937–30944.
93. Blalock, J.E.; Bost, K.L. Binding of peptides that are specified by complementary RNAs. Biochem. J. 1986, 234, 679–689.
94. Tropsha, A.; Kizer, J.S.; Chaiken, I.M. Making sense from antisense: A review of experimental data and developing ideas on sense-antisense peptide recognition. J. Mol. Recognit. 1992, 5, 43–54.
95. Biro, J.C. The Proteomic Code: A molecular recognition code for proteins. Theor. Biol. Med. Model. 2007, 4, 45.
96. Sela-Culang, I.; Ofran, Y.; Peters, B. Antibody specific epitope prediction-emergence of a new paradigm. Curr. Opin. Virol. 2015, 11, 98–102.
97. Sela-Culang, I.; Kunik, V.; Ofran, Y. The structural basis of antibody-antigen recognition. Front. Immunol. 2013, 4, 302.
98. Kunik, V.; Ofran, Y. The indistinguishability of epitopes from protein surface is explained by the distinct binding preferences of each of the six antigen-binding loops. Prot. Eng. Des. Sel. 2013, 26, 599–609.
99. Blythe, M.J.; Flower, D.R. Benchmarking B cell epitope prediction: Underperformance of existing methods. Prot. Sci. 2005, 14, 246–248.
100. Hopp, T.P. Retrospective: 12 years of antigenic determinant predictions, and more. Pept. Res. 1993, 6, 183–190.
101. Van Regenmortel, M.H.V.; Pellequer, J.-L. Predicting antigenic determinants in proteins: Looking for unidimensional solutions to a three-dimensional problem? Pept. Res. 1994, 7, 224–228.
102. Ponomarenko, J.V.; Van Regenmortel, M.H.V. B cell epitope prediction. In Structural Bioinformatics, 2nd ed.; Gu, J., Bourne, P.E., Eds.; John Wiley: Hoboken, NJ, USA, 2009; pp. 849–879.
103. Mariuzza, R.A. Multiple paths to multispecificity. Immunity 2006, 24, 359–361.
104. Zhou, Z.H.; Zhang, Y.; Hu, Y.F.; Wahl, L.M.; Cisar, J.O.; Notkins, A.L. The broad antibacterial activity of the natural antibody repertoire is due to polyreactive antibodies. Cell Host Microbe 2007, 1, 51–61.
105. Manivel, V.; Bayiroglu, F.; Siddiqui, Z.; Salunke, D.M.; Rao, K.V. The primary antibody repertoire represents a linked network of degenerate antigen specificities. J. Immunol. 2002, 169, 888–897.
106. Mouquet, H.; Nussenzweig, M.C. Polyreactive antibodies in adaptive immune responses to viruses. Cell. Mol. Life Sci. 2012, 69, 1435–1445.
107. Dimitrov, J.D.; Planchais, C.; Roumenina, L.T.; Vassilev, T.L.; Kaveri, S.V.; Lacroix-Desmazes, S. Antibody polyreactivity in health and disease: Statuvariabilis. J. Immunol. 2013, 191, 993–999.
108. Thorpe, I.F.; Brooks, C.L., 3rd. Molecular evolution of affinity and flexibility in the immune system. Proc. Natl. Acad. Sci. USA 2007, 104, 8821–8826.
109. Wardemann, H.; Yurasov, S.; Schaefer, A.; Young, J.W.; Meffre, E.; Nussenzweig, M.C. Predominant autoantibody production by early human B cell precursors. Science 2003, 301, 1374–1377.
110. Notkins, A.L. Polyreactivity of antibody molecules. Trends Immunol. 2004, 25, 174–179.
111. Sandberg, J.K.; Franksson, L.; Sundbäck, J.; Michaelsson, J.; Petersson, M.; Achour, A.; Wallin, R.P.A.; Sherman, N.E.; Bergman, T.; Jörnvall, H.; et al. T cell tolerance based on avidity thresholds rather than complete deletion allows maintenance of maximal repertoire diversity. J. Immunol. 2000, 165, 25–33.
112. Leng, Q.; Bentwich, Z. Beyond self and nonself: Fuzzy recognition of the immune system. Scand. J. Immunol. 2002, 56, 224–232.
113. Bramwell, V.W.; Perrie, Y. The rational design of vaccines. Drug Discov. Today 2005, 10, 1527–1534.
114. D’Argenio, D.A.; Wilson, C.B. A decade of vaccines: Integrating immunology and vaccinology for rational vaccine design. Immunity 2010, 33, 437–440.
115. Douek, D.C.; Kwong, P.D.; Nabel, G.J. The rational design of an AIDS vaccine. Cell 2006, 124, 677–681.
116. Schief, W.R.; Ban, Y.E.; Stamatatos, L. Challenges for structure-based HIV vaccine design. Curr. Opin. HIV AIDS 2009, 4, 431–440.
117. Sattentau, Q.J.; McMichael, A.J. New templates for HIV-1 antibody-based vaccine design. F1000 Biol. Rep. 2010, 2, 60.
118. Nabel, G.J.; Kwong, P.D.; Mascola, J.R. Progress in the rational design of an AIDS vaccine. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2011, 366, 2759–2765.
119. Kuntz, I.D. Structure-based strategies for drug design and discovery. Science 1992, 257, 1078–1082.
120. Amzel, L.M. Structure-based drug design. Curr. Opin. Biotechnol. 1998, 9, 366–369.
121. Gschwend, D.A.; Good, A.C.; Kuntz, I.D. Molecular docking towards drug discovery. J. Mol. Recognit. 1996, 9, 175–186.
122. Wlodawer, A. Rational approach to AIDS drug design through structural biology. Annu. Rev. Med. 2002, 53, 595–614.
123. De Clercq, E. The history of antiretrovirals: Key discoveries over the past 25 years. Rev. Med. Virol. 2009, 19, 287–299.
124. James, L.C.; Roversi, P.; Tawfik, D.S. Antibody multi-specificity mediated by conformational diversity. Science 2003, 299, 1362–1367.
125. Sperling, R.; Francus, T.; Siskind, G.W. Degeneracy of antibody specificity. J. Immunol. 1983, 131, 882–885.
126. Parnes, O. From interception to incorporation: Degeneracy and promiscuous recognition as precursors of a paradigm shift in immunology. Mol. Immunol. 2004, 40, 985–991.
127. Wucherpfennig, K.W.; Allen, P.M.; Celada, F.; Cohen, I.R.; De Boer, R.; Garcia, K.C.; Goldstein, B.; Greenspan, R.; Hafler, D.; Hodgkin, P.; et al. Polyspecificity of T cell and B cell receptor recognition. Semin. Immunol. 2007, 19, 216–224.
128. Van Regenmortel, M.H.V. The rational design of biological complexity: A deceptive metaphor. Proteomics 2007, 7, 965–975.
129. Wu, X.; Yang, Z.Y.; Li, Y.; Hogerkorp, C.M.; Schief, W.R.; Seaman, M.S.; Zhou, T.; Schmidt, S.D.; Wu, L.; Xu, L. et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010, 329, 856–861.
130. Diskin, R.; Scheid, J.F.; Marcovecchio, P.M.; West, A.P., Jr.; Klein, F.; Gao, H.; Gnanapragasam, P.N.; Abadir, A.; Seaman, M.S.; Nussenzweig, M.C. et al. Increasing the potency and breadth of an HIV antibody by using structure-based rational design. Science 2011, 334, 1289–1293.
131. Van Regenmortel, M.H.V. Basic research in HIV vaccinology is hampered by reductionist thinking. Front. Immunol. 2012, 3, 194.
132. Van Regenmortel, M.H.V. Why does the molecular structure of broadly neutralizing monoclonal antibodies isolated from individuals infected with HIV-1 not inform the rational design of an HIV-1 vaccine? AIMS Public Health 2015, 2, 183–193.
133. Ayala, F.J. Debating Design: From Darwin to DNA; Dembski, W.A., Ruse, M., Eds.; Cambridge University Press: Cambridge, UK, 2004; pp. 55–80.
134. Ruse, M. Darwin and Design: Does Evolution Have a Purpose? Harvard University Press: Cambridge, MA, USA, 2002.
135. Burton, D.R.; Stanfield, R.L.; Wilson, I.A. Antibody vs. HIV in a clash of evolutionary titans. Proc Natl. Acad. Sci. USA 2005, 102, 14943–14948.
136. Van Regenmortel, M.H.V. The metaphor that viruses are living is alive and well, but it is no more than a metaphor. Stud. Hist. Philos. Sci. Part C Stud. Hist. Philos. Biol. Biomed. Sci. 2016.
137. Berzofsky, J.A. Intrinsic and extrinsic factors in protein antigenic structure. Science 1985, 229, 932–940.
138. Kuhn, T.S. The Structure of Scientific Revolutions; University of Chicago Press: Chicago, IL, USA, 1962; pp. 1–264.
139. Bird, A. Thomas Kuhn. In The Stanford Encyclopedia of Philosophy. Available online: http://plato.stanford.edu/entries/thomas-kuhn/ (accessed on 1 July 2016).
140. Popper, K. The Logic of Scientific Discovery; Hutchinson: London, UK, 1959; pp. 1–513.
141. Buchbinder, S.P.; Mehrotra, D.V.; Duerr, A.; Fitzgerald, D.W.; Mogg, R.; Li, D.; Gilbert, P.B.; Lama, J.R.; Marmor, M.; del Rio, C. et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): A double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008, 372, 1881–1893.
142. Esparza, J. What has 30 years of HIV research taught us? Vaccines 2013, 1, 513–526.
143. Van Regenmortel, M.H.V. An outdated notion of antibody specificity is one of the major detrimental assumptions of the structure-based reverse vaccinology paradigm, which prevented it from developing an effective HIV-1 vaccine. Front. Immunol. 2014, 5, 593.
144. Burton, D.R.; Desrosiers, R.C.; Doms, R.W.; Feinberg, M.B.; Gallo, R.C.; Hahn, B.; Hoxie, J.A.; Hunter, E.; Korber, B.; Landay, A.; et al. Public Health. A sound rationale needed for phase III HIV-1 vaccine trials. Science 2004, 303, 316.
145. Jefferys, R.; Harrington, M. Outstanding questions on HIV vaccine trial. Science 2004, 305, 180.
146. Rerks-Ngarm, S.; Pitisuttithum, P.; Nitayaphan, S.; Kaewkungwal, J.; Chiu, J.; Paris, R.; Premsri, N.; Namwat, C.; de Souza, M.; Adams, E. et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 2009, 361, 2209–2220.
147. Esparza, J. A new scientific paradigm may be needed to finally develop an HIV vaccine. Front. Immunol. 2015, 6, 124.
148. McElrath, M.J.; Haynes, B.F. Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity 2010, 33, 542–554.
149. Bush, V. Science, the Endless Frontier: A Report to the President on a Program for Hostwar Scientific Research; National Science Foundation: Washington, DC, USA, 1945.
150. Stokes, D.E. Pasteur’s Quadrant. Basic Science and Technological Innovation; Brooking Institution Press: Washington, DC, USA, 1997; pp. 1–196.
151. Esparza, J. The global HIV vaccine enterprise. Int. Microbiol. 2005, 8, 93–101.
152. Van Regenmortel, M.H.V.; Andrieu, J.M.; Dimitrov, D.S.; Ensoli, B.; Hioe, C.E.; Moog, C.; Ruprecht, R.M. Paradigm Changes and the Future of HIV Vaccine Research: A Summary of a Workshop Held in Baltimore on 20 November 2013. J. AIDS Clin. Res. 2014, 5, 281.
153. Mokyr, J. Technology and the Problem of Human Knowledge. In The Gifts of Athena. Historical Origins of the Knowledge Economy; Princeton University Press: Princeton, UK, 2002; pp. 1–27.
154. Yu, L.; Guan, Y. Immunologic basis for long HCDR3s in broadly neutralizing antibodies against HIV-1. Front. Immunol. 2014, 5, 250.
155. Briney, B.S.; Willis, J.R.; Crowe, J.E. Human peripheral blood antibodies with long HCDR3s are established primarily at original recombination using a limited subset of germline genes. PLoS ONE 2012, 7, e36750.
156. Hacking, I. Representing and Intervening; Cambridge University Press: Princeton, NJ, USA, 1983; pp. 1–304.
157. Van Regenmortel, M.H.V. Reductionism and complexity in molecular biology. Scientists now have the tools to unravel biological complexity and overcome the limitations of reductionism. EMBO J. 2004, 5, 1016–1020.
158. Mazzocchi, F. Complexity in biology. EMBO Rep. 2008, 9, 10–14.
159. Gannon, F. Too complex to comprehend? EMBO Rep. 2007, 8, 705.
160. Kelley, L.; Scott, M. The evolution of biology: A shift towards the engineering and prediction-generating tools and away from traditional research practice. EMBO Rep. 2008, 9, 1163–1167.
161. Chalmers, A.F. What Is This Thing Called Science, 3rd ed.; Open University Press: Maidenhead, UK, 1999; pp. 1–288.
162. Popper, K.R. Conjectures and Refutations; Routledge and Kegan Paul: London, UK, 1969; pp. 1–412.
163. Horgan, J. The End of Science; Broadway Books: New York, NY, USA, 2006; pp. 32–41.
164. Klee, R. Introduction to the Philosophy of Science. Cutting Nature at its Seams; Oxford University Press: New York, NY, USA, 1997; pp. 41–61.
165. Cartwright, N. How the Laws of Physics Lie; Oxford University Press: New York, NY, USA, 1983; pp. 1–221.
166. Alm, E.; Arkin, A.P. Biological networks. Curr. Opin. Struct. Biol. 2003, 13, 193–202.
167. Van Regenmortel, M.H.V. Reductionism and the search for structure-function relationships in antibody molecules. J. Mol. Recognit. 2002, 15, 240–247.
168. Jones, O.W.; Nirenberg, M.W. Degeneracy in the amino acid code. Biochem. Biophys. Acta 1966, 119, 400–406.
169. Cohn, M. Degeneracy, mimicry and cross-reactivity in immune recognition. Mol. Immunol. 2005, 42, 651–655.
170. Medawar, P.B.; Medawar, J.S. The Life Science; Granada Publishing: London, UK, 1978.
171. Mazumdar, P.H. Species and Specificity; Cambridge University Press: Cambridge, UK, 1995.
172. Silverstein, A.M. History of immunology: Development of the concept of immunologic specificity: II. Cell. Immunol. 1982, 71, 183–195.
173. Day, E.D. Advanced Immunochemistry, 2nd ed.; John Wiley and Sons: New York, NY, USA, 1990; pp. 1–291.
174. Van Regenmortel, M.H.V. From absolute to exquisite specificity. Reflections on the fuzzy nature of species, specificity and antigenic sites. J. Immunol. Meth. 1998, 216, 37–48.
175. Frank, S.A. Immunology and Evolution of Infectious Disease; Princeton University Press: Princeton, UK, 2002; p. 42.
176. Klasse, P.J. How to assess the binding strength of antibodies elicited by vaccination against HIV and other viruses. Exp. Rev. Vaccines 2016, 15, 295–311.
177. Alexander, M.R.; Ringe, R.; Sanders, R.W.; Voss, J.E.; Moore, J.P.; Klasse, P.J. What do chaotrope-based avidity assays for antibodies to HIV-1 envelope glycoproteins measure? J. Virol. 2015, 89, 5981–5995.
178. Van Oss, C.J. Antigen-antibody interaction. In Structure of Antigens; Van Regenmortel, M.H.V., Ed.; CRC Press: Boca Raton, FL, USA, 1992; Volume 1, pp. 99–125.
179. Zeder-Lutz, G.; Benito, A.; Van Regenmortel, M.H.V. Active concentration measurements of recombinant biomolecules using biosensor technology. J. Mol. Recognit. 1999, 12, 300–309.
180. VanCott, T.C.; Bethke, F.R.; Polonis, V.R.; Gorny, M.K.; Zolla-Pazner, S.; Redfield, R.R.; Birx, D.L. Dissociation rate of antibody-gp120 binding interactions is predictive of V3-mediated neutralization of HIV-1. J. Immunol. 1994, 153, 449–459.
181. Van Regenmortel, M.H.V.; Azimzadeh, A. Determination of antibody affinity. In Immunochemistry; van Oss, C.J., Van Regenmortel, M.H.V., Eds.; Marcel Dekker: New York, NY, USA, 1994; pp. 805–828.
182. Talmage, D.W. Immunological specificity, unique combinations of selected natural globulins provide an alternative to the classical concept. Science 1959, 129, 1643–1648.
183. Richards, F.F.; Konigsberg, W.H.; Rosenstein, R.W.; Varga, J.M. On the specificity of antibodies. Science 1975, 187, 130–137.
184. Schubert, W.; Bonnekoh, B.; Pommer, A.J.; Philipsen, L.; Böckelmann, R.; Malykh, Y.; Gollnick, H.; Friedenberger, M.; Bode, M.; Dress, A.W.M. Analyzing proteome topology and function by automated multi-dimensional fluorescence microscopy. Nat. Biotechnol. 2006, 24, 1270–1278.
185. Schubert, W. Systematic, spatial imaging of large multimolecular assemblies and the emerging principles of supramolecular order in biological systems. J. Mol. Recognit. 2014, 27, 3–18.
186. Greenspan, N.S. Antigen mimicry with anti-idiotypic antibodies. In Structure of Antigens; Van Regenmortel, M.H.V., Ed.; CRC Press: Boca Raton, FL, USA, 1992; Volume 1, pp. 55–79.
187. Van Regenmortel, M.H.V.; Muller, S. Synthetic Peptides as Antigens; Elsevier: Amsterdam, The Netherlands, 1999; pp. 1–381.
188. Muller, S.; Plaue, S.; Couppez, M.; Van Regenmortel, M.H.V. Comparison of different methods for localizing antigenic regions in histone H2A. Mol. Immunol. 1986, 23, 593–601.
189. Van Regenmortel, M.H.V. Transcending the structuralist paradigm in immunology-affinity and biological activity rather than purely structural considerations should guide the design of synthetic peptide epitopes. Biomed. Pept. Protein Nucleic Acids 1995, 1, 109–116.
190. Mariuzza, R.A.; Phillips, S.E.; Poljak, R.J. The structural basis of antigen-antibody recognition. Annu. Rev. Biophys. Chem. 1987, 16, 139–159.
191. Rini, J.M.; Schulze-Gahmen, U.; Wilson, I.A. Structural evidence for induced fit as a mechanism for antibody-antigen recognition. Science 1992, 255, 959–965.
192. Getzoff, E.D.; Tainer, J.A.; Lerner, R.A.; Geysen, H.M. The chemistry and mechanism of antibody binding to protein antigens. Adv. Immunol. 1988, 43, 1–98.
193. Ramsland, P.A.; Guddat, L.W.; Edmundson, A.B.; Raison, R.L. Diverse binding site structures revealed in homology models of polyreactive immunoglobulins. J. Comput. Aided Mol. Des. 1997, 11, 453–461.
194. Yin, J.; Beuscher, A.E., 4th; Andryski, S.E.; Stevens, R.C.; Schultz, P.G. Structural plasticity and the evolution of antibody affinity and specificity. J. Mol. Biol. 2003, 330, 651–656.
195. Khan, T.; Salunke, D.M. Structural elucidation of the mechanistic basis of degeneracy in the primary humoral response. J. Immunol. 2012, 188, 1819–1827.
196. Westhof, E.; Altschuh, D.; Moras, D.; Bloomer, A.C.; Mondragon, A.; Klug, A.; Van Regenmortel, M.H.V. Correlation between segmental mobility and the location of antigenic determinants in proteins. Nature 1984, 311, 123–126.
197. Tainer, J.A.; Getzoff, E.D.; Paterson, Y.; Olson, A.J.; Lerner, R.A. The atomic mobility component of protein antigenicity. Annu. Rev. Immunol. 1985, 3, 501–535.
198. Uversky, V.N.; Oldfield, C.J.; Dunker, A.K. Showing your ID: Intrinsic disorder as an ID for recognition, regulation and cell signaling. J. Mol. Recognit. 2005, 18, 343–384.
199. Saunders, C.J.; McCaffrey, R.A.; Zharkikh, I.; Kraft, Z.; Malenbaum, S.E.; Burke, B.; Cheng-Mayer, C.; Stamatatos, L. The V1, V2, and V3 regions of the human immunodeficiency virus type 1 envelope differentially affect the viral phenotype in an isolate-dependent manner. J. Virol. 2005, 79, 9069–9080.
200. Javaherian, K.; Langlois, A.J.; McDanal, C.; Ross, K.L.; Eckler, L.I.; Jellis, C.L.; Profy, A.T.; Rusche, J.R.; Bolognesi, D.P.; Putney, S.D.; et al. Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. Proc. Natl. Acad. Sci. USA 1989, 86, 6768–6772.
201. Spear, G.R.; Takefman, D.M.; Sharpe, S.; Ghassemi, M.; Zolla-Pazner, S. Antibodies to the HIV-1 V3 loop in serum from infected persons contribute a major proportion of immune effect or functions including complement activation, antibody binding, and neutralization. Virology 1994, 204, 609–615.
202. Sharon, M.; Kessler, N.; Levy, R.; Zolla-Pazner, S.; Goërlach, M.; Anglister, J. Alternative conformations of HIV-1 V3 loops mimic β hairpins in chemokines, suggesting a mechanism for coreceptor selectivity. Structure 2003, 11, 225–236.
203. Gorny, M.K.; Williams, C.; Volsky, B.; Revesz, K.; Cohen, S.; Polonis, V.R.; Honnen, W.J.; Kayman, S.C.; Krachmarov, C.; Pinter, A.; et al. Human monoclonal antibodies specific for conformation sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades. J. Virol. 2002, 76, 9035–9045.
204. VanCott, T.C.; Polonis, V.R.; Loomis, L.D.; Michael, N.L.; Nara, P.L.; Birx, D.L. Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1. AIDS Res. Hum. Retrovir. 1995, 11, 1379–1391.
205. Zolla-Pazner, S. Identifying epitopes of HIV-1 that induce protective antibodies. Nat. Rev. Immunol. 2004, 4, 199–210.
206. Gorny, M.K.; Williams, C.; Volsky, B.; Revesz, K.; Wang, X.H.; Burda, S.; Kimura, T.; Konings, F.A.; Nádas, A.; Anyangwe, C.A. et al. Cross-clade neutralizing activity of human anti-V3 monoclonal antibodies derived from the cells of individuals infected with non-B clades of human immunodeficiency virus type. J. Virol. 2006, 80, 6865–6872.
207. Stanfield, R.; Cabezas, E.; Satterthwait, A.; Stura, E.; Profy, A.; Wilson, I. Dual conformations for the HIV-1 gp120 V3 loop in complexes with different neutralizing fabs. Structure 1999, 7, 131–142.
208. Rosen, O.; Chill, J.; Sharon, M.; Kessler, N.; Mester, B.; Zolla-Pazner, S.; Anglister, J. Induced fit in HIV-neutralizing antibody complexes: Evidence for alternative conformations of the gp120 V3 loop and the molecular basis for broad neutralization. Biochemistry 2005, 44, 7250–7258.
209. Mor, A.; Segal, E.; Mester, B.; Arshava, B.; Rosen, O.; Ding, F.X.; Russo, J.; Dafni, A.; Schvartzman, F.; Scherf, T.; et al. Mimicking the structure of the V3 epitope bound to HIV-1 neutralizing antibodies. Biochemistry 2009, 48, 3288–3303.
210. Mester, B.; Manor, R.; Mor, A.; Arshava, B.; Rosen, O.; Ding, F.X.; Naider, F.; Anglister, J. HIV-1 peptide vaccine candidates: Selecting constrained V3 peptides with highest affinity to antibody 447–52D. Biochemistry 2009, 48, 7867–7877.
211. Van Regenmortel, M.H.V. Limitations to the structure-based design of HIV-1 vaccine immunogens. J. Mol. Recognit. 2011, 24, 741–753.
212. Korkut, A.; Hendrickson, W.A. Structural plasticity and conformational transitions of HIV envelope glycoprotein gp120. PLoS ONE 2012, 7, e52170.
213. Pancera, M.; Zhou, T.; Druz, A.; Georgiev, I.S.; Soto, C.; Gorman, J.; Huang, J.; Acharya, P.; Chuang, G.Y.; Ofek, G. et al. Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Nature 2014, 514, 455–461.
214. Julien, J.P.; Cupo, A.; Sok, D.; Stanfield, R.L.; Lyumkis, D.; Deller, M.C.; Klasse, P.J.; Burton, D.R.; Sanders, R.W.; Moore, J.P. et al. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science 2013, 342, 1477–1483.
215. Zolla-Pazner, S.; Cohen, S.S.; Boyd, D.; Kong, X.P.; Seaman, M.; Nussenzweig, M.; Klein, F.; Overbaugh, J.; Totrov, M. Structure/function studies involving the V3 region of the HIV-1 envelope delineate multiple factors that affect neutralization sensitivity. J. Virol. 2016, 90, 636–649.
216. Upadhyay, C.; Mayr, L.M.; Zhang, J.; Kumar, R.; Gorny, M.K.; Nádas, A.; Zolla-Pazner, S.; Hioe, C.E. Distinct mechanisms regulate exposure of neutralizing epitopes in the V2 and V3 loops of HIV-1 envelope. J. Virol. 2014, 88, 12853–12865.
217. Kwong, P.D.; Doyle, M.L.; Casper, D.J.; Cicala, C.; Leavitt, S.A.; Majeed, S.; Steenbeke, T.D.; Venturi, M.; Chaiken, I.; Fung, M. et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 2002, 420, 678–682.
218. Munro, J.B.; Gorman, J.; Ma, X.; Zhou, Z.; Arthos, J.; Burton, D.R.; Koff, W.C.; Courter, J.R.; Smith, A.B., 3rd; Kwong, P.D. et al. Conformational dynamics of single HIV-1 envelope trimers on the surface of native virions. Science 2014, 346, 759–763.
219. Munro, J.B.; Mothes, W. Structure and Dynamics of the Native HIV-1 Env Trimer. J. Virol. 2015, 89, 5752–5755.
220. Muller, S. Immunization with peptides. In Synthetic Peptides as Antigens; Van Regenmortel, M.H.V., Muller, S., Eds.; Elsevier: Amsterdam, The Netherlands, 1999; pp. 113–177.
221. Scherer, E.M.; Leaman, D.P.; Zwick, M.B.; McMichael, A.J.; Burton, D.R. Aromatic residues at the edge of the antibody combining site facilitate viral glycoprotein recognition through membrane interactions. Proc. Natl. Acad. Sci. USA 2010, 107, 1529–1534.
222. Greenspan, N.S. Design challenges for HIV-1 vaccines based on humoral immunity. Front. Immunol. 2014, 5, 335.
223. Foote, J.; Eisen, H.N. Kinetic and affinity limits on antibodies produced during immune responses. Proc. Natl. Acad. Sci. USA 1995, 92, 1254–1256.
224. Batista, F.D.; Neuberger, M.S. Affinity dependence of the B cell response to antigen: A threshold, a ceiling, and the importance of off-rate. Immunity 1998, 8, 751–759.
225. Cohn, M.; Langman, R.E. The Protecton: The evolutionary selected unit of humoral immunity. Immunol. Rev. 1990, 115, 1–131.
226. Tauber, A.I. The Immune Self: Theory or Metaphor; Cambridge University Press: Cambridge, UK, 1997; pp. 1–354.
227. Jerne, N. Towards a network theory of the immune system. Annal. Immunol. 1974, 125C, 373–389.
228. Cohen, I.R.; Hershberg, U.; Solomon, S. Antigen-receptor degeneracy and immunological paradigms. Mol. Immunol. 2004, 40, 993–996.